• Encapsulated Living Cells For Diabetes: The Final Push?

    “There are two elements that I’m familiar with which relate to Sigilon in particular. We have a technology that hides implants from the immune system so that the immune system won’t attack those implants. That means for the first time now we can manufacture cellular implants so you can do things like the artificial pancreas, which is what we did with Eli Lilly & Co.. Or you can manufacture implants that become cell factories, which can do things like treat hemophilia by manufacturing Factor VIII or Factor IX.”

    Scrip April 5, 2018
  • Lilly to Fund Sigilon Therapeutics’ Encapsulated Cell Research to Treat Type 1 Diabetes

    In April, insulin maker Eli Lilly announced it would invest up to $473 million in Sigilon Therapeutics and the cell encapsulation technology the Cambridge, Mass., biotech company is developing was big news in the type 1 diabetes space. We’ve been following this encapsulation technology since I met with Arturo Vegas in 2015, when he was a chemistry post doc at MIT working Robert Langer and  Daniel Anderson at the Koch Institute for Integrative Cancer Research.

    A Sweet Life June 5, 2018
  • A New Way to Deliver Proteins

    Paul Wotton, Ph.D., CEO of Sigilon Therapeutics, discusses his company’s approach for delivering cells that avoid immune detection.

    Encapsulated cell therapy is an emerging area of biopharmaceutical research that aims to unleash the therapeutic potential of cells…

    PharmaVOICE Innovator’s Corner June 1, 2018
  • Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes

    In patients who suffer from Type I diabetes, pancreatic beta cells are killed off by the immune system. Lilly and Sigilon plan to encapsulate induced pluripotent stem cells that are engineered into insulin-producing pancreatic beta cells. Ultimately, the companies hope, these products can restore a person’s insulin production without alarming their immune system.

    Drug Delivery Business News April 4, 2018

    Sigilon Therapeutics Inc. (Cambridge, Mass.) granted Eli Lilly and Co. (NYSE:LLY) exclusive, worldwide rights to Sigilon’sType I diabetes program in a deal potentially worth over $470 million.

    BioCentury April 4, 2018
  • BBJ Sigilon

    Fast-growing Cambridge biotech Sigilon inks $63M diabetes deal with Eli Lilly

    The startup is developing what it calls “living therapeutics” — drugs based on engineered cells that can fight a range of disorders when implanted in the body.

    Boston Business Journal April 4, 2018
  • Eli Lilly jumps into a $473M hunt with Sigilon for the Holy Grail in diabetes cell therapies

    Today Sigilon is announcing a $473 million pact with Eli Lilly — which is stepping out under a bolder R&D chief in Dan Skovronsky — to drive their stem cell work on Type 1 diabetes into the clinic, with $63 million of that in an upfront and the rest divvied up with a goal of fully funding the development of a durable new therapy for the disease.

    Endpoints April 4, 2018
  • Interview with Devyn Smith PhD, COO of Sigilon Therapeutics

    Medgadget editor Tom Peach recently spoke with Devyn Smith PhD, Chief Strategy Officer of Sigilon Therapeutics, to learn more about the company’s technology.

    Medgadget March 13, 2018
  • The Innovation Distinction

    “Biotechs are surrounded by innovation; they make science fiction—a digital pill, 3D printing, wearable technology—a reality; are located in trendy tech hubs like San Francisco, San Diego, and Boston; and most importantly, they offer hope.”

    Pharmaceutical Executive February 4, 2018
  • BBJ Sigilon

    Cambridge VC Firm Flagship Targets $500M for Latest Fund

    A few months ago, Flagship unveiled Sigilon Therapeutics, a Cambridge startup that is aiming to develop a new class of “living therapeutics”

    Boston Business Journal September 15, 2017

We are proud to be invited to speak at conferences about our technology. Below are some of the conferences where you can see and learn more about us:

Peer-reviewed publications describing Sigilon Therapeutics’s research include: